Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Grohe

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Deutsche Medizinische Wochenschrift (1946)|September 24, 2010
[Chronic thromboembolic pulmonary hypertension: recommendations of the Cologne Consensus Conference 2010]H Wilkens, I Lang, J Behr, et al.
ESMO Open|September 15, 2022
The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus reportM C Hardenberg, B Patel, C Matthews, et al.
Deutsche Medizinische Wochenschrift (1946)|December 10, 2014
[Pulmonary arterial hypertension--a disease of the immune system?]G Riemekasten, W M Kuebler, R Schermuly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerA Kron, C Alidousty, M Scheffler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]S Novello, V Torri, C Grohe, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Deutsche Medizinische Wochenschrift (1946)|September 24, 2010
[Chronic thromboembolic pulmonary hypertension: recommendations of the Cologne Consensus Conference 2010]H Wilkens, I Lang, J Behr, et al.
ESMO Open|September 15, 2022
The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus reportM C Hardenberg, B Patel, C Matthews, et al.
Deutsche Medizinische Wochenschrift (1946)|December 10, 2014
[Pulmonary arterial hypertension--a disease of the immune system?]G Riemekasten, W M Kuebler, R Schermuly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerA Kron, C Alidousty, M Scheffler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]S Novello, V Torri, C Grohe, et al.
Pageof 2